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A B S T R A C T
Reactive oxygen species have emerged as key participants in a broad range of physiological and pathophysio-
logical processes, not least within the vascular system. Diverse cellular functions which have been attributed to
some of these pro-oxidants within the vasculature include the regulation of blood pressure, neovascularisation
and vascular inﬂammation. We here highlight the emerging roles of the enzymatically-generated reaction
oxygen species, O2- and H2O2, in the regulation of the functions of the gaseous signalling molecules: nitric oxide
(NO), carbon monoxide (CO), and hydrogen sulphide (H2S). These gasotransmitters are produced on demand
from distinct enzymatic sources and in recent years it has become apparent that they are capable of mediating a
number of homeostatic processes within the cardiovascular system including enhanced vasodilation, angiogen-
esis, wound healing and improved cardiac function following myocardial infarction. In common with O2- and/or
H2O2 they signal by altering the functions of target proteins, either by the covalent modiﬁcation of thiol groups
or by direct binding to metal centres within metalloproteins, most notably haem proteins. The regulation of the
enzymes which generate NO, CO and H2S have been shown to be inﬂuenced at both the transcriptional and post-
translational levels by redox-dependent mechanisms, while the activity and bioavailability of the gasotransmit-
ters themselves are also subject to oxidative modiﬁcation. Within vascular cells, the family of nicotinamide
adenine dinucleotide phosphate oxidases (NAPDH oxidases/Noxs) have emerged as functionally signiﬁcant
sources of regulated O2- and H2O2 production and accordingly, direct associations between Nox-generated
oxidants and the functions of speciﬁc gasotransmitters are beginning to be identiﬁed. This review focuses on the
current knowledge of the redox-dependent mechanisms which regulate the generation and activity of these
gases, with particular reference to their roles in angiogenesis.
1. Introduction
The vascular system represents a closed circuit of vessels that
collectively transports oxygen and nutrients to all tissues. This delivery
system has evolved multiple mechanisms that allow it to adapt to
dynamic changes in tissue physiology in order to ensure that the supply
of oxygen and nutrients matches the tissue demand at any given time
[1]. One way in which this is achieved is through the growth of new
blood vessels from the existing vasculature in a multistep, highly
coordinated process known as angiogenesis. In this process, activated
(“sprouting”) endothelial cells (from either arterial or venous vessels)
release proteases which degrade the underlying basement membrane
and subsequently migrate into the extracellular matrix. Adjacent
endothelial cells in turn proliferate, diﬀerentiate and form luminal
tubes which eventually fuse to the pre-established vascular network
[2]. These adaptive responses are biochemically coordinated by a
number of cell signalling mediators, most notably the vascular en-
dothelial growth factor (VEGF) family of protein growth factors [3].
VEGF targets the endothelium to initiate angiogenesis and comprises
multiple isoforms of which VEGF-A is a key regulator of vessel growth
which has been shown to induce endothelial cell growth and survival
both in vitro and in vivo [4–6]. The central role of VEGF-A in
physiological angiogenesis (and vasculogenesis) has been demonstrated
during embryonic and early postnatal development [6] as well as in
pathological angiogenesis seen in solid tumour formation [7]. At the
biochemical level, the eﬀects of VEGF are mediated via its binding to
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endothelial-expressed, plasma membrane-bound, tyrosine kinase recep-
tors, Flt-1 (VEGFR-1) and primarily, Flk-1/KDR (VEGFR-2). VEGF
binding to VEGFR-2 initiates its autophosphorylation, dimerization
and the subsequent activation of its tyrosine kinase domain [8]. This
in turn activates downstream signalling cascades, including the MEK-
ERK1/2 pathway to support cell growth and proliferation [4] as well as
the anti-apoptotic phosphoinositide 3-kinase- (PI3-K-)Akt pathway to
promote cell survival [5] (Fig. 1).
Increased VEGF-dependent signalling triggers the angiogenic re-
sponse and therefore the control of VEGF expression is critical to the
regulation of angiogenesis. In this regard, the transcriptional regulation
of VEGF appears to play the pre-eminent role, and multiple transcrip-
tion factors which are positive mediators of VEGF transcription have
been identiﬁed, together with cellular agents which stimulate their
activity through diverse signalling pathways [9]. An important stimulus
for angiogenesis is tissue hypoxia and, accordingly, VEGF is a known
direct transcriptional target of hypoxia-inducible factor 1 (HIF-1).
Similarly, the expressions of other known pro-angiogenic factors
including angiopoietin 1 and 2, stromal cell-derived factor-1 (SDF-1),
placenta growth factor and platelet-derived growth factor B are also
known to be upregulated by HIF-1 [10,11].
These regulatory pathways, both upstream and downstream of the
action of VEGF, have been extensively studied and emerging data
indicate the involvement of redox-dependent molecular signalling
mechanisms at multiple stages [12]. Further, angiogenic responses
have increasingly been shown to be mediated in part by the biological
actions of a small family of gases, termed “gasotransmitters”, which are
enzymatically generated within vascular cells [13]. The precise me-
chanisms of the regulation of action of these short-lived mediators,
which comprise nitric oxide (NO), carbon monoxide (CO) and hydrogen
sulphide (H2S) are not currently fully understood. However, there is
growing evidence that their generation may be regulated in part by
redox-dependent mechanisms, while their chemical nature in some
cases makes them highly susceptible to oxidation. In this review we
summarise the current knowledge of the biochemistry which links
reactive oxygen species generation, redox signalling and the action of
the gasotransmitters in angiogenesis. A more comprehensive under-
standing of these mechanisms would be of great potential beneﬁt in
identifying new therapeutic targets for both cancer and vascular
diseases such as peripheral arterial disease (PAD) [14].
1.1. Reactive oxygen species and redox-signalling
Reactive oxygen species are partial reduction products of molecular
oxygen (O2) and include superoxide (O2-), hydrogen peroxide (H2O2)
and the hydroxyl radical (•OH) (Fig. 2). Historically, they have been
thought of as merely potentially detrimental by-products of aerobic
metabolism in the mitochondria or the result of unregulated uncoupling
of various O2-dependent enzymatic reactions [15]. The harmful biolo-
gical eﬀects of these oxidants are countered by the actions of enzymatic
and non-enzymatic antioxidants that collectively form the cellular
antioxidant system. Enzymatic antioxidants include superoxide dismu-
tase (SOD) that removes O2-, as well as catalase, peroxiredoxin and
glutathione peroxidase (GPx) that metabolise H2O2 [16]. Non-enzy-
matic antioxidants include vitamins C and E as well as the major redox
buﬀer, glutathione (GSH). GSH is present at millimolar concentrations
in the cell and scavenges both H2O2 and free radicals through the
formation of oxidised GSH (GSSG). The “steady state” cellular redox
status is maintained through the balance of constitutively expressed
pro-oxidants and these antioxidant systems (reviewed in [17]).
However it is now understood that physiological, enzymatic sources
of H2O2 and O2- exist which generate these species in a tightly regulated
and localised fashion. Moreover, the short-lived, regulated production
of these pro-oxidants can mediate various homeostatic aspects of
intracellular and extracellular function [18,19]. Both O2- and H2O2
are capable of orchestrating a variety of cell signalling responses that
culminate in a broad range of phenotypic outcomes such as altered
proliferation, adhesion and invasion of endothelial cells. Thus they can
act as intracellular second messengers in various signalling pathways to
control cell function. Due to diﬀerences in the chemical properties of
each type of oxidant species, such as half-life and lipid solubility, not all
reactive oxygen species are able to function as eﬃcient signalling
mediators [20]. For example, O2- has a short half-life of only 1 μS and is
Fig. 1. A schematic illustration of hypoxia- and VEGF-mediated signalling in the endothelium leading to angiogenesis through the promotion of cell survival and proliferation. In response
to hypoxia, the upregulation of HIF-1α leads to increased expression of a number of pro-angiogenic factors including SDF-1, PDGF-B, angiopoietin, placenta growth factor and
importantly VEGF. VEGF signals have been the best characterised and have been shown to cause the stimulation of VEGFR2 within the endothelium. In turn this activates downstream
signalling pathways including P13K/Akt and MEK/MAPK to promote pro-angiogenic cellular responses.
Fig. 2. Reactive oxygen species. A diagrammatic illustration depicting the gradual
reduction of molecular oxygen (O2), through its sequential gain of electrons, to form
water. As oxygen is reduced various reactive oxygen species are generated in the process
including superoxide (O2-), hydrogen peroxide (H2O2) and hydroxyl radicals (•OH).
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membrane-impermeable due to its polarity. Therefore its signalling
capacity is limited. By contrast, H2O2 is more stable and has a relatively
long half-life of 10 μS. It can freely permeate biological membranes and
has emerged as the major redox metabolite mediating redox signalling
events [21]·H2O2 acts to modulate numerous cellular processes via
diverse mechanisms including the regulation of gene transcription,
mRNA and/or protein stability, intracellular traﬃcking and protein
activity [22]. The precise mechanisms which underlie the regulation of
the generation of H2O2 and the speciﬁcity of its action are not fully
understood. However it is clear that in complex metazoan systems, the
modulation of redox-signalling events must include intracellular com-
partmentalisation and gradients of the oxidative signal, together with
diﬀerential reactivity of the target sensors and bioavailability of
buﬀering thiol peroxidase systems [21,22].
Physiological redox signals are transmitted though the reversible
oxidative modiﬁcation of target proteins to alter conformation and
function·H2O2 can act to modify cysteine residues on redox-sensitive
proteins [23] that possess reactive thiol groups which exhibit a low pKa
[18] (Fig. 3). A number of diﬀerent types of H2O2-induced, post-
translational modiﬁcations exist, including those that involve the
sequential oxidation of a thiol which proceeds through sulphenic acid
(SOH), sulphinic acid (SO2H) and sulphonic acid (SO3H) states [24]
(Fig. 3). In addition to these modiﬁcations, H2O2 can also induce
covalent intra- and inter-disulphide bond formation to elicit a func-
tional change (Fig. 3) [25,26]. Of these oxidation states, cysteine-
sulphenic acids and disulphides are readily reversible via the cell's
intrinsic glutathione and thioredoxin antioxidant systems, while cy-
steine-sulphinic acid derivatives, (once thought to be irreversible), can
also be reduced the action of sulﬁredoxins [27]. By contrast, cysteine
sulphonic acid modiﬁcations are not known to be reversible. Both O2-
and H2O2 can also react with metal centres, often located within the
active sites of target proteins. For example, H2O2 can react with a Mn-
Fe centre in the active site of protein phosphatase-1 leading to its
inhibition [28].
1.2. Functional vascular sources of reactive oxygen species: NADPH
oxidases
Within vascular cells, O2- and H2O2 is derived from a number of
enzymatic sources including the mitochondrial electron transport
system, cytochrome p450, xanthine oxidase and uncoupled nitric oxide
synthase (NOS). As stated above, the O2- derived from these sources is
generally considered to be the result of mis-regulated metabolic
functions, although there is some evidence for its potential functional
importance in some cellular signalling pathways. By contrast, the
family of ﬂavoenzymes known as Nicotinamide Adenine Dinucleotide
Phosphate Oxidases (NAPDH oxidases/Noxs) generate O2- or, in some
cases, H2O2 in a tightly regulated manner as their sole biological
function [29]. The prototype NADPH oxidase, originally identiﬁed in
phagocytes, comprises the membrane-associated catalytic gp91phox
(now termed Nox2) and regulatory p22phox subunits, in addition to the
cytosolic subunits; p47phox, p67phox and p40phox together with the
small GTPase, Rac1. Nox homologues were subsequently identiﬁed in
non-phagocytic cells, and in humans, NADPH oxidases now comprise a
known family of 7 multi-subunit transmembrane proteins (each con-
taining a distinct catalytic subunit; Nox1-5 or duox 1 and 2) which
display distinct cell-type and subcellular expression patterns [29,30].
Each catalytic Nox subunit contains at least 6 transmembrane alpha
helices and, with the exception of Nox5 and duox1/2, all isoforms
associate with p22phox. However, diﬀerent Nox isoforms additionally
associate with other varied regulatory proteins which modulate their
regulation and function. For example, p22phox can associate with
Polymerase Delta Interacting Protein 2 [31] to activate Nox4 in smooth
muscle cells (SMCs) whereas Nox1 activation is mediated by association
with Nox organiser 1 (NOXO1) and Nox activator 1 (NOXA1) [32].
Mechanistically, all the Nox subunits shuttle electrons from NADPH
down an electrochemical gradient across a membrane to molecular
oxygen (O2) which is subsequently reduced to superoxide (O2-) [33,34].
However, in the case of some Noxs (such as Nox4 and duox1/2) the O2-
that is produced is very rapidly converted to H2O2. The exact mechan-
ism(s) by which this is achieved is still unclear although some studies
suggest that Nox4 may be capable of mediating an intrinsic superoxide
dismutase activity [35]. O2- or H2O2 newly-generated by Noxs can be
utilised by the cell in order to elicit tightly-controlled, cellular
responses [29,30,36]. Moreover, the diﬀerences in structure, activity,
expression, regulation and the type of oxidant species produced enable
each speciﬁc Nox protein to direct its own distinct and deﬁned
functions [37–39].
Nox proteins are expressed in all of the component cell types of the
vascular wall. SMCs express Nox1, Nox4 and Nox5 whereas the
endothelium contains 4 Nox isoforms; Nox1, Nox2 (including the
associated phagocytic subunits), Nox4 and Nox5 [40]. Their distinct
physiological (and pathophysiological) roles in vascular function have,
in some cases, been demonstrated in mouse models in vivo. For instance,
genetic ablation of Nox1 or Nox2 was shown to elicit beneﬁcial eﬀects
on hypertension and vascular dysfunction in certain pathophysiological
settings [41–45]. By contrast, deﬁciency of Nox4 in mice acted to
promote angiotensin II-dependent vascular dysfunction, suggesting that
Nox4-generated H2O2 plays a protective role in vascular cells [46]. The
diﬀerent functions of Nox2 and Nox4 within the vasculature have been
further illustrated by the contrasting phenotypes of transgenic (TG)
mice which overexpress these genes speciﬁcally within endothelial
cells. Thus we demonstrated that endothelial-speciﬁc overexpression of
Nox2 (directed by the Tie2 promoter) resulted in increased blood
pressure in mice after angiotensin II infusion, and attenuated acetylcho-
line- (Ach-)induced vasorelaxation in isolated aortas [47]. Meanwhile
Tie2-mediated overexpression of Nox4 within endothelial cells acted to
reduce basal blood pressure within TG mice, and enhanced endothelial-
dependent vasodilation ex-vivo [48]. Therefore Nox4 is increasingly
considered to be a positive regulator of vascular homeostasis
[48,46,49], and in this regard it may be signiﬁcant that it is abundantly
Fig. 3. H2O2-induced post-translational modiﬁcations. A schematic diagram indicat-
ing H2O2-induced post-translational modiﬁcations of a cysteine thiol moiety. The pKa,
which is a measure of hydrogen dissociation from a given thiol, is determined by the
microenvironment in which the thiol is situated, with basic surrounding amino acids
tending to deprotonate the thiol more eﬃciently than acidic amino acids A) The
progressive oxidation of a deprotonated, reactive thiol by H2O2 proceeding through
sulphenic, sulphinic and sulphonic acid states. B) Inter and Intra-molecular disulphide
bond formation. These modiﬁcations lead to functional changes within a protein.
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expressed in the endothelium, compared to other Nox isoforms
[39,50,51].
1.3. Reactive oxygen species and redox signalling in angiogenesis
There is now a large body of evidence which demonstrates that both
O2- and H2O2 participate in redox-dependent signalling pathways
which can modulate angiogenic responses both in vitro and in vivo.
Early in vitro studies demonstrated that topical application of H2O2 to
bovine thoracic aortic endothelial cells (BAECs) enhanced proliferation,
migration and tube formation compared to controls and that these
eﬀects could be ablated by the administration of catalase [52]. Perhaps
signiﬁcantly, it has been reported that these H2O2-induced angiogenic
responses occur in a biphasic manner, with low concentrations of H2O2
enhancing angiogenic phenotypes and higher concentrations inhibiting
them [53]. In addition, as might be expected from their very diverse
properties, there is speciﬁcity with regard to the angiogenic eﬀects of
individual reactive oxidant species. For example, O2- and H2O2 were
shown to be both pro- and anti-angiogenic at varying concentrations,
whereas •OH was found only to exert anti-angiogenic eﬀects, or to have
no eﬀect at all at low concentrations [53].
Many studies have now shown that some reactive oxygen species
can promote the induction of VEGF expression in both endothelial and
smooth muscle cells [54,55]. In addition, VEGF (and other angiogenic
growth factors such as angiopoietin-1) have been shown to elicit
angiogenic cellular responses via O2-- and/or H2O2-dependent molecu-
lar mechanisms [56]. VEGF-induced endothelial cell sprouting,
mediated via Transforming growth factor-β-activated-kinase 1 (TAK1),
was also shown to involve the increased expression of (mitochondrial-
expressed) SOD2. The functional involvement of H2O2 (generated by
SOD2) was demonstrated as the impaired angiogenesis, observed in
aortic rings in which endothelial TAK1 was ablated, could be rescued by
the overexpression of SOD2 [57]. Thus reactive oxygen species are
involved in the regulation of cellular angiogenic responses, both
upstream and downstream of the induction of VEGF expression. In
vivo, a potential role for H2O2 in angiogenesis was ﬁrst demonstrated in
extra-cellular-SOD-transgenic mice, which displayed increased H2O2
production and angiogenesis in a murine model of hind-limb ischemia
[58]. Moreover, increased H2O2, VEGF production and Akt phosphor-
ylation, associated with the promotion of physiological pulmonary
angiogenesis, was also observed in exercise-trained rats [59].
1.4. Vascular NADPH oxidases and angiogenesis
The physiological sources of reactive oxygen species which regulate
angiogenic cellular processes are potentially varied, and there is
evidence for the involvement of O2- and H2O2 derived from several
diﬀerent sources in some in vitro settings. For instance, the stimulation
of human retinal endothelial cells with high levels of glucose increased
VEGF expression and cell proliferation in a manner dependent on
mitochondrial O2- production from the electron transport chain (ETC)
[60]. Moreover, a recent study demonstrated that treatment of human
umbilical vein endothelial cells (HUVECs) with VEGF signiﬁcantly
elevated mitochondrial H2O2 production and subsequent cell migration
[61]. In addition, the inhibition of endogenous xanthine oxidase was
shown to reduce VEGF-stimulated Akt phosphorylation in HUVECs
suggesting that xanthine oxidase may also be important for VEGF-
induced endothelial cell survival [62]. However the major sources of
O2- and H2O2 which function as signalling molecules in the angiogenic
processes in vascular cells are recognised as the NADPH oxidases [56].
The (patho)physiological importance of Nox1, 2 and 4 in angiogenic
processes in vivo has, in each case, been demonstrated. Global genetic
ablation of Nox1 was shown to impair tumour angiogenesis in mice
[63], while (again global) genetic deletion of Nox2 or Nox4 was
reported to reduce blood ﬂow recovery in ischemic mouse hindlimb
models [46,64]. Nox4 expression was further shown to be required to
support exercise-induced angiogenesis in mice [65]. However, in a
recent study in which the consequences of the ablation of Nox1,2 or 4
were assessed in a slow-growing mouse tumour model, only Nox4 was
found to contribute positively to angiogenesis. By contrast, ablation of
Nox2 had no eﬀect, and deletion of Nox1 actually enhanced angiogen-
esis [66]. The signiﬁcance of the apparent discrepancies in these
ﬁndings is not clear, but likely reﬂects the diﬀerent experimental
models adopted. The physiological importance speciﬁcally of Nox4 in
angiogenesis is further evidenced by endothelial-speciﬁc TG over-
expression of Nox4 in mice which demonstrated increased angiogenesis
in an ischemic hind limb model [49]. Accordingly, in vitro, Nox4
overexpression was shown to increase endothelial cell proliferation,
migration and tube formation [49,67]. It is perhaps also signiﬁcant that
Nox4 is an inducible gene, whose transcriptional expression is activated
by hypoxia [49,67]. This clearly may have relevance with regard to its
potential functional role in the regulation of angiogenesis.
At the molecular level, the mechanisms which underlie the angio-
genic functions of Noxs have been extensively studied in vitro. Nox-
dependent upregulation of HIF1α and VEGF expression via Akt and
ERK1/2 activation in prostate cancer cells was demonstrated by siRNA-
mediated targeting of the common p22 phox subunit [68]. In the
speciﬁc case of Nox1, overexpression in NIH3T3 ﬁbroblasts promoted
VEGF and VEGFR expression in an H2O2-dependent manner [69]. The
(mRNA and protein) expression of Nox1 was also shown to be increased
by hypoxia in A549 (epithelial) cells, which in turn resulted in
increased HIF expression (the transcriptional activator of VEGF), that
could be blocked by catalase, or the ﬂavoprotein inhibitor diphenylene
iodonium (DPI). Both Nox1 and Nox2 are activated by the small
GTPase, Rac1 [29]. AGS cells (gastric cancer cells) in which Rac1
expression had been depleted showed reduced expression of both HIF-
1α and VEGF, while media conditioned by these cells inhibited cell
proliferation when applied to human endothelial cells ( [70]). A
potential function for Nox4 in the upstream activation of VEGF
expression has also been demonstrated, as siRNA-mediated inhibition
of Nox4 expression resulted in decreased HIF2-α and VEGF promoter
activity in HEK-293 ﬁbroblasts [71]. In addition, overexpression of
Nox4 in human microvascular endothelial cells (HMVECs) was suﬃ-
cient to increase VEGF mRNA levels, while downregulation of Nox4
decreased the level of (HIF-1α-dependent) VEGF expression after
insulin stimulation [72].
There are also many reports of the involvements of Noxs in the
signalling pathways downstream of VEGF and other pro-angiogenic
growth factors. VEGF and angiopoietin-1 have been shown to stimulate
endothelial cell migration in a Nox2-dependent manner [73,74]. In
addition, Nox4 was shown to mediate VEGF-dependent angiogenic
reponses in human microvascular endothelial cells in vitro, by enhan-
cing receptor tyrosine kinase phosphorylation and the activation of
ERK1/2 [75]. Moreover in a separate study, VEGF stimulation resulted
in a physical interaction between phosphorylated VEGFR2 and Nox4
that promoted STAT3-dependent proliferation of endothelial cells [76].
Finally, a study by Evangelista et al. demonstrated that VEGF induced
endothelial migration in a Nox4- and Nox2-dependent manner and that
this involved the S-glutathiolation of SERCA2b which subsequently
increased Ca2+ inﬂux into endothelial cells [77]. The precise protein
targets of Nox-generated O2- and/or H2O2 which are susceptible to
oxidation and act to modulate the angiogenic responses in endothelial
cells are not known. However it has been demonstrated that H2O2
produced by ectopic expression of extracellular SOD (ecSOD) can
increase VEGF-induced phosphorylation of VEGFR2 via the oxidative
inactivation of protein tyrosine phosphatase 1B (PTP1B) (a negative
regulator of VEGFR2 signalling) [58]. It is of note that in many separate
studies PTP1B has also been shown to be a target of oxidative
modiﬁcation by Nox4 [78,79]. In addition to PTP1B, VEGFR2 has also
been shown to have redox-sensitive cysteine residues in its kinase
domain [80] and it has been suggested that H2O2 can induce the
formation of an inhibitory intramolecular disulphide bond in VEGFR2
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[81]. However the functional signiﬁcance of this with respect to the
cellular angiogenic responses to H2O2 remains to be determined.
A central principle in intracellular redox-signalling mechanisms is
the localization of the (freely diﬀusible) signalling molecules close to
their targets. The enzyme complexes generating these signals (such as
H2O2-generating Nox4), must therefore be localised to speciﬁc intra-
cellular compartments in order to eﬀect speciﬁc responses. The
subcellular location of Nox4 has been the subject of some controversy,
and has been reported, in disparate cells types, in the nucleus,
endoplasmic reticulum (ER), mitochondria, focal adhesions and plasma
membrane (reviewed in [82]). The underlying reasons for these
discrepancies may reﬂect cell-type speciﬁc diﬀerencies in Nox4 func-
tion, or the poor speciﬁcity of available antibodies. However, in the
case of the Nox4-dependent oxidation of PTP1B, (described above), it
has been shown that the co-localization of Nox4 and PTP1B within the
ER of endothelial cells was a functional requirement [78].
1.5. Gasotransmitters
It is now known that in addition to the involvement of reactive
oxygen species (highlighted above) another group of endogenously-
produced small molecules appear to be important for vascular re-
sponses both in vitro and in vivo, including angiogenesis, cell survival
and the regulation of vascular tone [83–85]. Collectively termed
“gasotransmitters”, NO, CO and H2S comprise a group of small
molecule signalling agents which were previously known as toxic gases
[86] but are now recognised as physiological regulators and eﬀectors in
diverse biological processes. They have become the subject of much
research and are now recognised to contribute to signalling pathways in
angiogenesis both upstream and downstream of VEGF (and other
angiogenic growth factor) expression as described below.
The term gasotransmitters is, however, somewhat misleading as
these molecules are completely soluble at physiologically-relevant
concentration and pH and so perhaps should not be considered to be
gases in these circumstances. None-the-less, their discovery and the
characterisation of their mechanisms of action has altered the conven-
tional paradigm of intercellular signalling. Unlike conventional signal-
ling molecules (such as peptides) that are often stored in vesicles,
gasotransmitters are generated on demand by distinct enzymes.
Furthermore, peptide signals tend to mediate their function by binding
to plasma membrane receptors such as receptor tyrosine kinases. By
contrast, gasotransmitters can diﬀuse across membranes both within
and between cells and subsequently interact with their protein target(s)
directly to modify structure and function [84]. In this regard they share
similar properties with some reactive oxygen species, most notably
H2O2. Their biochemical targets (in common with both O2- and/or
H2O2) are redox metal centres (most notably iron-containing haem
proteins) and redox-active amino acids such as cysteine thiol groups.
Chemical reactions between the gasotransmitters and some reactive
oxygen species (such as the reaction between O2- and NO to form
peroxynitrite (NOO-)), together with signiﬁcant commonality in their
targets, results in a signiﬁcant interdependence between these groups of
signalling molecules in their biological functions [87]. Thus the speciﬁc
chemical properties and reactivity of the signalling oxidant molecules
and the gasotransmitters have been utilised together to modulate
complex signalling pathways as is beginning to become apparent.
As stated above, gasotransmitters must be synthesised, as required,
close to their speciﬁc sites of action [84] and therefore both the
expression and the activity of their biosynthetic enzymes must be
tightly controlled. Within the vascular system, the relevant enzymes
involved in the generation of these gases are endothelial nitric oxide
synthase (eNOS) for NO [88], haem oxygenase-1 (HO-1) for CO [89]
and cystathionine gamma-lyase (CSE) for H2S [90] (Fig. 4). In addition
to the modulation of function of the gasotransmitters by their direct
reactivity (in some cases) with O2- and/or H2O2, there is also increasing
evidence that the expression and/or function of each of these biosyn-
thetic enzymes is regulated by redox-dependent mechanisms. Therefore
the gasotransmitters should, as a group, be considered to be important
eﬀectors of redox-dependent signalling mechanisms which regulate the
angiogenic cellular responses, as detailed below.
1.6. Nitric oxide (NO)
In 1980, Furchgott and Zawadzki published their seminal research
on the function of the endothelium in vasomotion. Here it was
demonstrated that an intact endothelium is absolutely required for
the mediation of ACh-induced vasorelaxation in rabbit aortic rings
[91]. These observations deﬁned a role for the endothelium in the
production of a vasoactive substance termed endothelial-derived relax-
ing factor (EDRF) [91] which was subsequently identiﬁed as NO [92].
Since then the study of signalling by NO has expanded exponentially
and many important physiological roles within the cardiovascular
system have been ascribed to this gaseous mediator [93].
NO is synthesised enzymatically by a family of enzymes collectively
termed nitric oxide synthases (NOS). The NOS family encompasses
three distinct isoenzymes encoded by separate genes that include
neuronal NOS (nNOS, NOS-I), inducible NOS (iNOS, NOS-II) and
endothelial NOS (eNOS, NOS-III). eNOS is constitutively-expressed
within endothelial cells [94] and utilises the amino acid L-arginine as
a substrate for the production of NO and L-citrulline under physiolo-
gical conditions [95]. Numerous agonists have been shown to induce
eNOS activation, including ACh, serotonin, PPARs, bradykinin, hista-
mine, Ca2+ ionophores, adiponectin, VEGF, ﬂuid shear stress and
hypoxia [96,97]. NOS enzymes comprise an N-terminal oxygenase
domain with binding sites for haem, L-arginine and tetrahydrobiopterin
(BH4), and a reductase domain which binds NADPH, ﬂavin mononu-
cleotide (FMN), FAD, and calmodulin (CaM) (reviewed in [96]). The
active eNOS enzyme is a homo-dimer containing a zinc ion, tetra-
hedrally co-ordinated to cysteine residues at the surface of the dimer
[98]. Under quiescent conditions it is anchored to caveolae through its
interaction with caveolin-1, and its activation is dependent upon
Ca2+/CaM, which binds to and displaces eNOS from caveolin, resulting
in a conformational change that promotes the movement of electrons
from NADPH to the haem moiety in the reductase domain [99]. Its
activity can be modulated by numerous posttranslational modiﬁcations
including phosphorylation at multiple serine, threonine and tyrosine
sites [96], palmitylation, glutathionylation, and S-nitrosylation, and
association with other proteins such as heat shock protein 90 (Hsp90)
[100]. The bioavailability of its substrate, L-arginine and the BH4 co-
factor are additionally crucial determinants of eNOS function. Indeed,
loss of BH4 results in eNOS uncoupling and subsequent generation of
O2- [101].
1.7. The role of nitric oxide in angiogenesis
Once formed in the endothelium, NO diﬀuses to neighbouring SMCs
where it activates soluble guanylate cyclase (sGC) by binding to its
haem group. sGC converts guanosine triphosphate (GTP) into cyclic
guanosine monophosphate (cGMP) which then activates Protein Kinase
G (PKG). PKG has a number of downstream targets that act to cause
SMC relaxation [102]. The importance of eNOS in controlling vasodila-
tion and blood pressure is highlighted by the vessel-constrictive eﬀects
of competitive eNOS inhibitors such as NG-monomethyl-L-arginine (L-
NMMA) and NG-nitro-L-arginine-methyl ester (L-NAME) on endothe-
lium-induced vasodilation in ex vivo experiments [103], and the clinical
use of these inhibitors in the diagnosis of endothelial dysfunction [104].
Direct genetic evidence for eNOS-induced control of blood pressure was
conﬁrmed in mice by disruption of the eNOS gene, since these mice
displayed enhanced systemic blood pressure compared to wild-type
(WT) controls [105]. In addition to its well-established role in regulat-
ing vascular tone, NO has also been shown to be a mediator of post-
natal angiogenesis (Table 1). Mice in which eNOS has been genetically
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ablated develop normally, but display a severe form of critical limb
ischemia in mouse hindlimb models [106,107], together with impaired
wound healing and defective angiogenesis [108]. Both angiogenic and
arteriogenic responses to hindlimb ischemia were severely blunted in
eNOS-/- mice, an eﬀect that could be rescued by adenoviral-mediated
delivery of a constitutively-active form of eNOS [109].
There is much evidence to support NO-mediating signalling events
downstream of VEGF. Thus HUVEC form capillary-like structures when
stimulated with VEGF, an eﬀect that can be blocked by the NOS
antagonist, L-NAME [110]. In vivo, mice with genetic ablation of the
eNOS gene (eNOS-/-) demonstrated reduced capillary growth in im-
planted collagen plugs, and impaired angiogenic responses to hindlimb
ischemia compared to control animals, and in both cases the phenotype
could not be rescued by administration of VEGF [106,111]. In addition,
VEGF-induced angiogenesis was shown to be blocked by L-NAME in a
rabbit cornea model of angiogenesis [112]. Mechanistically, the
activation of (human) eNOS is associated with phosphorylation at
Ser615, Tyr81, Ser633 and Ser1177 [113–116], and has been shown to be
mediated by the actions of multiple protein kinases, including Akt/PKB,
PKA, c-Src and AMPK [117,118]. Activation of VEGFR2 in endothelial
cells (by VEGF binding) results in the Akt-dependent phosphorylation
of eNOS at Ser1177 [113,119], while VEGF treatment of BAECs resulted
in the phosphorylation of eNOS at Ser617 and Ser635 (equivalent to
human Ser615 and Ser 633) [116]. The kinase responsible for phosphor-
ylation of Ser617 in this study was suggested also to be Akt, while
phosphorylation at Ser633 (of human eNOS) has recently been shown to
be mediated, in response to VEGF signalling by the serine/threonine-
protein kinase, Pim1 [120]. In addition, VEGF-signalling induces the c-
Src-dependent phosphorylation and association of Hsp90 with eNOS
[121], eNOS is additionally activated by other stimuli, including shear
stress [122], which has been shown to be dependent on both Akt- and
PKA-dependent mechanisms. NO is believed to promote angiogenesis
by a sGC-cGMP-dependent pathway(s), although the precise mechan-
isms remain to be fully elucidated [123]. There is also evidence that NO
can act upstream of VEGF signalling to promote angiogenesis. Thus
increased NO, either administered by exogenous NO donors, or due to
induction or overexpression of NOS, acted in vascular smooth muscle
cells (VSMCs) in vitro to increase VEGF expression [124,125]. In
addition, inhibition of NOS in vivo eliminated the increased expression
of VEGF (and VEGFR-2) in electrically stimulated capillary growth in
rat muscle for up to 4 days [126]. Mechanistically, NO has been shown
to activate the VEGF promoter via the cis-regulatory hypoxia response
element (HRE) which mediates the transactivation of VEGF transcrip-
tion by HIF-1 [127]. It should be noted, however, that in an ex vivo
model of balloon angioplasty in rat thoracic aortae, increased VEGF
expression was inhibited by NO donors [128] and the reasons for the
discrepancies in these observations is currently not clear.
In recent years it has become apparent that asymmetric dimethy-
Fig. 4. Gasotransmitters. A schematic diagram depicting the major gasotransmitters and their respective enzymatic sources and subcellular locations. A) The relevant vascular sources of
these gases are eNOS for NO, HO-1 for CO and CSE for H2S. eNOS: Endothelial Nitric Oxide Synthase, nNOS: Neuronal Nitric Oxide Synthase, iNOS: Inducible Nitric Oxide Synthase, HO-
1: Haem oxygenase-1, CSE: Cystathionine-γ-lyase, CBS: Cystathionine-β-synthase, and 3MST: 3 mercaptopyruvate sulphur transferase. B) Intracellularly, eNOS is located in caveolae at
the plasma membrane, HO-1 can be found in caveolae and the nucleus, CSE and CBS are located in the cytoplasm and may also be found in the nucleus and mitochondria. CAT and MST
are located in the mitochondria.
Table 1
A summary of the angiogenic eﬀects of each gasotransmitter and its respective synthetic enzyme, both in vitro and in vivo/ex vivo. MI: Myocardial Infarction, CORM: CO releasing
molecule, L-NAME: NG-nitro-L-arginine-methyl ester, SDF-1: stromal cell-derived factor-1.
Gasotransmitter Role in angiogenesis (In Vitro) Reference
eNOS/NO HUVEC form capillary-like structures when stimulated with VEGF, and this is blocked by L-NAME. [110]
Overexpression of eNOs, or NO-donors promoted VEGF expression in VSMCs which could act in a paracrine manner to promote endothelial cell
proliferation
[125]
HO/CO HO-1 overexpression enhanced endothelial proliferation. [174]
HO-1 gene silencing reduced capillary formation, an eﬀect rescued by CORM. [89]
CO gas or CORM-2 inhibited VEGF-dependent angiogenic responses in HUVECs [175]
CORM-2 promoted angiogenic responses in HUVECs, upstream of VEGF [176]
Chemical inhibition of HO reduced angiogenic activities of endothelial cells both upstream and downstream of VEGF [177,180]
HO-1 silencing perturbed VEGF-dependent angiogenic responses in endothelial cells [182]
CSE/H2S Exogenous H2S increased HUVEC proliferation. [90]
NaHS administration promoted angiogenic responses in cultured endothelial cells [232]
Gasotransmitter Role in angiogenesis (In Vivo/Ex Vivo) Reference
eNOS/NO eNOS-/- mice show reduced capillary growth in implanted collagen plugs [111]
eNOS-/- mice show impaired angiogenic responses after hindlimb ischemia [106,107]
VEGF-induced angiogenesis is blocked by L-NAME in rabbit cornea [112]
HO/CO Ablation of HO-1 in mice prevented capillary sprouting in aortic rings in response to SDF-1 [183]
HO1 inhibition blocks angiogenesis in solid tumours in rats. [185]
HO-1 is necessary for post-injury reparative neovascularization after hind-limb ischemia and cutaneous wounding in mice [187,188]
CSE/H2S NaHS administration increased neovascularisation and haemoglobin content of Matrigel plugs in mice. [183]
NaHS administration promoted angiogenesis after hindlimb ischemia in rats [233]
Microvessel formation in aortic rings and wound healing was impaired in CSE-/- mice. [90]
NaHS administration improved wound-healing in type-2 diabetic mice [234]
R.K. Mistry, A.C. Brewer Free Radical Biology and Medicine 108 (2017) 500–516
505
larginine (ADMA) and its associated metabolic enzymes dimethylargi-
nine dimethylaminohydrolase I and II (DDAHI and DDAHII) can
regulate angiogenesis through their eﬀects on NOS substrate bioavail-
ability [129,130]. ADMA is an endogenous methylated form of L-
arginine that acts as a competitive inhibitor of all NOS enzymes, and is
formed from the hydrolysis of proteins that have been methylated on
arginine residues. DDAHI and II are enzymes that metabolise ADMA
and therefore negate its inhibitory eﬀects on NOS, elevating NO levels
[131]. Both in vitro and in vivo studies have demonstrated that DDAH
enzymes are involved in angiogenesis. Aortic rings isolated from DDAHI
heterozygous mice (DDAH+/-) showed reduced sprouting in Matrigel.
This eﬀect could be mimicked through the addition of ADMA to ring
explants from WT mice, suggesting that endogenous removal of ADMA
by DDAHI is required for vessel growth [132]. Moreover, endothelial-
speciﬁc ablation of DDAHI blunted angiogenesis both in vitro and in vivo
[133], while gene-targeted over-expression of DDAHI enhanced NO
production and angiogenesis in a murine model of hindlimb ischemia
that was associated with reduced ADMA levels [134].
1.8. Regulation of nitric oxide-dependent signalling by redox mechanisms
The relationship between reactive oxygen species and the signalling
functions of NO is complex, and species-type dependent. NO bioavail-
ability is considered to be a fundamental requirement for vascular
health [135]. It has long been known that O2- readily reacts with NO to
form NOO-, and so acts to reduce NO bioavailability, thereby contribut-
ing to vascular disease aetiology [136]. Indeed, Nox1- and Nox2-
derived O2- is thought to inactivate NO and enhance hypertension
[42–45] and vascular dysfunction in angiotensin II-induced stress
[137]. Nox2 activity has also been shown to directly reduce NO
bioavailability leading to enhanced plaque formation in a model of
atherosclerosis [138], while detrimental eﬀects of O2- on angiogenesis
have also been reported [139]. A more oxidising basal cellular redox
state can also act to modulate NOS enzymatic activity by direct
oxidation of the enzyme itself, via glutathionylation [140,141] or by
oxidation of its co-factor, BH4 [142]. In both cases this converts the
enzyme from a NOS to a superoxide-generating oxidase (or uncoupled
NOS), and the NADPH oxidase, Nox2 has been demonstrated to be a
potential oxidant source [141,143]. The responsiveness of the major
target of NO, sGC, can also be aﬀected by the cellular redox state. Thus
its ferrous haem can become oxidised to an NO-resistant ferric haem
which is susceptible to ubiquitylation and degradation [144].
By contrast to O2-, both exogenous and endogenously-generated
H2O2 have been shown in endothelial cells in vitro to promote both NO
production and NO-dependent signalling [145] and to stimulate
angiogenic responses (proliferation and migration) which are blocked
by inhibiting eNOS [146]. Moreover, in vivo, the transgenic over-
expression of catalase in mice demonstrated that endogenous, endothe-
lial-expressed H2O2 mediates the upregulation of eNOS after exercise
[147]. In BAECs H2O2 (but not O2-) was shown to increase both the rate
of transcription and the stability of eNOS mRNA in a dose- and time-
dependent manner [148]. These increases were shown to be prevented
by both the antioxidant N-acetylcysteine (NAC), and the H2O2 scaven-
ger, catalase, although the precise mechanisms of transcriptional
regulation remain unknown. H2O2 was also shown to be able to
upregulate eNOS activity through the modulation of signalling path-
ways that contribute to its activation via VEGF-dependent signalling.
Thus Thomas et al. demonstrated that H2O2 could induce the phos-
phorylation of eNOS at Ser1177, which is known to be necessary and
suﬃcient for VEGF-mediated endothelial cell migration, and this was
shown to occur via the PI3-K/Akt pathway, shown to be activated by
VEGF signalling (see above) [149]. Consistent with this, administration
of H2O2 to BAECs was suﬃcient to promote NO production via Akt and
Erk1/2 [150]. Independent of VEGF, H2O2 has also been shown to be a
critical intermediate mediating phosphorylation of eNOS via activation
of the G-protein-coupled receptor for ADP, P2Y1 [151]. H2O2 admin-
istration has also been shown to stimulate phosphorylation of bovine
eNOS at Tyr83 (equivalent to Tyr81 in human eNOS) in BAECs via Src
kinase, although it is unclear whether this is VEGF-dependent or
independent [117].
As stated previously, H2O2 is produced endogenously within
vascular cells from a number of enzymatic sources including, (perhaps
most notably in endothelial cells) Nox4. Indeed, Nox4 overexpression
has been shown to increase eNOS protein expression and activity in
cultured endothelial cells and to be suﬃcient to promote proliferation,
migration and tube formation [49]. Moreover, in vivo, endothelial-
speciﬁc Nox4-overexpressing mice demonstrated accelerated blood-
ﬂow recovery in an ischemic hindlimb model as well as enhanced
aortic capillary sprouting. Signiﬁcantly, these Nox4-induced eﬀects
were ablated by genetic deletion of eNOS [49]. Perhaps consistent with
these observations, global genetic ablation of Nox4 in mice resulted in
an approximately 50% decrease in eNOS expression in the carotid
artery, and signiﬁcantly-reduced NO production which potentially
contributed to the attenuated angiogenesis in these mice after femoral
artery ligation [46]. Taken together, these studies strongly suggest that
Nox4 is a physiological source of enzymatic H2O2 which acts to
promote post-natal angiogenic responses, at least in part, via modula-
tion of the expression of eNOS and/or modulation of VEGF-mediated
activation of eNOS activity (Fig. 5). In this regard, the potential Nox4-
generated H2O2-dependent oxidative inactivation of protein tyrosine
kinases, including PTP1B and SHP2 (negative regulators of VEGFR2
signalling) may be of functional signiﬁcance [78,79,152].
As mentioned above, the bioavailability of NO is also controlled by
DDAH enzymes. A recent study has suggested a role for the redox-
sensitive transcription factor, Nuclear factor erythroid 2-related factor
(Nrf2) in the coordinated regulation of both DDAH and eNOS in renal
glomerular endothelial cells [153]. Nrf2 is a basic leucine-zipper
transcription factor that is regulated by the cytoplasmic protein
Kelch-like ECH-associated protein 1 (KEAP1). In normal physiological
Fig. 5. Reactive oxygen species-dependent mechanisms regulating NO bioavail-
ability. A) H2O2 (potentially generated by Nox4) can increase eNOS expression via an
unknown mechanism leading to increased NO production. B) & C) Oxidant-dependent
activation of Nrf2 leads to increased transcription of eNOS (and therefore NO production)
and DDAH. Increased DDAH expression in turn acts to reduce ADMA (a competitive
inhibitor of NOS) levels resulting in increased NO production. D) H2O2 (potentially
generated by Nox4) potentiates the activation of the PI3K/Akt signalling pathway which
results in phosphorylation and activation of eNOS and increased NO production. E) O2- is
capable of reacting with NO to form peroxynitrite which reduces the bioavailability of
NO. F) Glutathionylation of eNOS under oxidative conditions and G) Oxidation of the
eNOS co-factor, BH4, leads to eNOS uncoupling, reduced NO production and O2-
production. The likely oxidant is O2- generated by Nox2. GSH: glutathione, GS:
glutathionylation, Pi: phosphorylation, BH4: tetrahydrobiopterin, DDAH: dimethylargi-
nine dimethylaminohydrolase, U.O: unidentiﬁed oxidant.
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conditions, KEAP1 sequesters Nrf2 in the cytoplasm where it is targeted
for ubiquitin-mediated degradation. However, upon activation by pro-
oxidants (among other stimuli), critical cysteine residues in KEAP1 are
oxidised resulting in the liberation of Nrf2 and its subsequent transloca-
tion to the nucleus where it drives the expression of a battery of
antioxidant and detoxifying genes [154]. The activation of Nrf2 using
tert-butylhydroquinone was demonstrated to enhance Nrf2 transloca-
tion to the nucleus and subsequent DDAHI and II expression [131]. This
eﬀect was lost upon Nrf2 ablation. In addition, concomitant with the
decrease in ADMA levels observed upon Nrf2 activation, both eNOS
expression and NO production increased (Fig. 5). It was concluded that
Nrf2 upregulates eNOS as well as DDAH enzymes to potentiate NO
production and improve endothelial cell function [153]. The physiolo-
gically relevant endogenous source(s) of the oxidant(s) which might
activate Nrf2 in this process is not known. However, we have shown
that increased Nox4 expression can act to promote the expression of
several Nrf2-target genes in other in vivo settings (see below) [155,156],
and therefore the increase of Nox4 expression seen in response to
hypoxia [49] may be of relevance here.
From these studies it is clear that both O2- and H2O2 play diverse
roles in the regulation of NO-dependent signalling, by regulating the
expression and activity of eNOS, together with the bioavailability and
functional capability of NO itself, and that these regulatory mechanisms
have functional consequences in angiogenic phenotypes (Fig. 5).
1.9. Carbon monoxide
CO, ﬁrst denoted as a ‘silent killer’, has come to be recognised as an
important physiological mediator in a broad range of biological
processes and systems, perhaps most notably in the neurological and
cardiovascular ﬁelds [157]. CO has high aﬃnity for haemoglobin, and
therefore its subsequent ability to reduce O2 transport in the blood led
to its initial characterisation as a toxic pollutant. However, it later
became apparent that CO can be generated physiologically by a family
of enzymes known as haem oxygenases (HOs) [158]. This family
comprises 3 isoenzymes, HO-1 [159], HO-2 [160] and HO-3 [161], of
which only HO-1 and −2 are thought to be catalytically-active
proteins. HO-1 is an inducible isoform which has been most closely
associated with CO-dependent signalling. Its expression and corre-
sponding activity is both positively and negatively regulated by a
number of stimuli including hypoxia [162,163], heat shock [164] and
oxidative stress [165]. It is noteworthy that these stimuli have species-
speciﬁc eﬀects, with hypoxia upregulating HO-1 in rat tissue [163] but
decreasing it in human cells [162]. HO-1 has been shown to be localised
to caveolae and cytosolic compartments of endothelial cells [166] as
well as the nucleus under conditions of “oxidative stress” [167]. By
contrast, HO-2 is constitutively expressed and is responsible for basal
CO production primarily in the brain and cardiovascular system [168].
Enzymatically, HO catalyses the rate-limiting step in the breakdown of
haem into biliverdin, iron and CO in a reaction that requires oxygen
and NADPH [169] Once formed, CO can subsequently induce a number
of targeted eﬀects as discussed below.
1.10. The role of carbon monoxide in angiogenesis
A number of vascular roles have been ascribed to CO including
reduced platelet activation [170] and monocyte-induced inﬂammation
[157]. In addition, CO has been implicated as a vasoactive mediator
that can induce vasorelaxation, an eﬀect which has been characterised
in a number of vessels including rat aorta [157] as well as mesenteric,
renal and pulmonary arteries [171] and has been demonstrated using
both CO donors and HO inhibitors [157]. The precise mechanisms by
which CO-dependent signalling occurs are not fully understood. How-
ever, in common with NO, CO is a non-polar molecule which can freely
diﬀuse across biological membranes and can bind sGC to modulate
cGMP production [87]. In addition, some groups have suggested that
CO-dependent signalling in the vasculature occurs in an endothelium-
dependent manner [172]. Therefore there is likely to be a great deal of
interdependence between the vascular functions of CO and NO.
In addition to vascular tone, HO/CO-signalling has also been
implicated in angiogenic control (Table 1). HO-1 expression is rapidly
induced in bovine aortic endothelial cells in response to hypoxia [173],
and early evidence for its functional signiﬁcance came from studies in
which HO-1 overexpression enhanced endothelial cell proliferation
[174]. By contrast, targeted gene silencing of HO-1 in endothelial cells
reduced capillary formation and cell proliferation. Re-introduction of
CO in the form of the CO donors, tricarbonyl-dichlororuthenium (II)
dimer (CORM-1) and tricarbonylchloro(glucinato)ruthenium (II)
(CORM-3), was suﬃcient to recover the angiogenic properties of HO-
1 deﬁcient endothelial cells [89]. CO-dependent signalling has been
reported to act both upstream and downstream of VEGF induction in
the angiogenetic response, although it should be noted that there
remain inconsistencies within the literature with regard to its pro- or
anti-angiogenic eﬀects [175–177]. This may reﬂect the diﬀerences in
cell types and/or diﬀerences in levels of CO applied to the cells [178].
Upstream of VEGF-signalling, HO-1 overexpression or activation has
been shown to increase VEGF production in VSMCs, macrophages and
endothelial cells [177,179] and accordingly treatment of endothelial
cells with CORM was shown to mimic this eﬀect [177]. Consistent with
this, inhibition of HO activity by tin protoporphyrin IX (SnPPIX)
abrogated the increase in VEGF expression in VSMCs, observed upon
stimulation by hypoxia, IL-1β or hemin [180], while ablation of HO-1
was shown to inhibit VEGF expression and the angiogenic responses of
endothelial cells [89]. By contrast, in a separate study, the hypoxic
induction of VEGF in rat aortic smooth muscle cells was shown to be
supressed by both CO and NO [181] in a sGC- and cGMP-mediated
pathway that resulted in decreased HIF-1 binding to the VEGF
enhancer. Downstream of VEGF signalling, CO has also been reported
to promote both pro- and anti-angiogenic eﬀects. Thus VEGF was
shown to induce sustained HO-1 expression and activity in cultured
endothelial cells, and the angiogenic responses induced by VEGF were
perturbed when HO-1 was inhibited [182]. However, in a more recent
study using HUVEC, exposure to CO was found to inhibit VEGF-induced
angiogenic responses [175]. Mechanistically, CO administration acted
to suppress VEGF-stimulated VEGFR-2 phosphorylation and the down-
stream Akt phosphorylation. The discrepancies in these observations
are likely to be due to diﬀerences in experimental design and remain to
be reconciled. HO-1 has also been shown to mediate the pro-angiogenic
eﬀects of SDF-1, through a protein kinase C-ζ-dependent, VEGF-
independent mechanism. Thus SDF-1 was shown to induce HO-1
expression in endothelial cells, and ablation of HO-1 in mice, in vivo,
prevented aortic rings forming capillary sprouts in response to SDF-1
[183]. Mechanistically, SDF-1 was shown to promote the phosphoryla-
tion of vasodilator-stimulated phosphoprotein (VASP) via HO-1 activa-
tion to promote angiogenesis. In addition to modulating the expression
and associated signalling pathways of pro-angiogenic factors, HO-1 has
also been shown to act to deplete the levels of the anti-angiogenic
factors, soluble fms-like tyrosine kinase I and soluble Endoglin, thereby
potentially further enhancing angiogenesis [184].
In vivo, a potential pro-angiogenic role of HO/CO-dependent
signalling has also been demonstrated. Thus the pan HO inhibitor, zinc
protoporphyrin (ZnPP) was found to block angiogenesis in solid
tumours suggesting a physiological role for HO in neovascularisation
[185]. In addition, the induction of HO-1 activity, or the administration
of a CO-donor both acted to promote formation of new coronary
arteries after myocardial infarction induced by coronary artery ligation
in rats [186]. In addition HO-1 was shown to be necessary for eﬃcient
post-injury reparative neovascularization after both hind-limb ischemia
[187] and cutaneous wounding in mice [188]. A critical role for HO-1
placental vascular formation during embryonic development is also
recognised. Thus HO-1 expression and endogenous CO production is
highly elevated in the placenta during pregnancy [189] and a partial
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deﬁciency of maternal HO-1 results (in mice) in the restriction of the
growth of both the placenta and the foetus that is due, at least in part, to
impaired angiogenesis [190].
The manipulation of the HO/CO axis using pharmacological and
genetic means has therefore implicated this pathway in the regulation
of angiogenesis. However little is known about the exact mechanism(s)
through which CO acts. As stated above, CO is believed to induce
changes in protein activity primarily through its reaction with haem
containing proteins [191], and both sGC and NOS have been implicated
as potential targets, again suggesting cross-talk between gasotransmit-
ters [192].
1.11. Regulation of carbon monoxide-dependent signalling by redox
mechanisms
It is well-established that pro-oxidant-generating stimuli such as
UVA radiation and cadmium chloride, in addition to H2O2 per se, are
capable of inducing HO gene expression [193]. Indeed, HO-1 expres-
sion has been used as a model system for studying redox-regulated gene
expression in mammalian cells [194]. Administration of H2O2 has been
demonstrated to enhance both HO-1 and VEGF expression in a variety
of cell types, including vascular cells, while chemical inhibition of HO-1
activity in part abrogated the increase in VEGF expression, underlying
the signiﬁcance of this redox-regulation to angiogenesis [195]. From
several studies it has become apparent that many redox-sensitive cell
signalling pathways and transcription factors are involved in regulating
HO-1 expression including Mitogen Activated Protein Kinases (MAPKs)
such as P38 [196] and JNK [197] as well as the transcription factor
Hypoxia Inducible Factor 1α (HIF1α) [163] and, perhaps most notably,
Nrf2 [156]. Cigarette smoke contains a number of pro-oxidants and
application of aqueous extracts to NIH3T3 cells induced Nrf2 activation
leading to HO-1 induction, an eﬀect that was lost when Nrf2 was
silenced [198]. Nrf2 has been shown to induce HO-1 transcription
through two distal cis-acting enhancer elements in the HO-1 promoter
that both contain Nrf2-binding consensus antioxidant response ele-
ments (AREs) [198]. The regulation of HO-1 in response to oxidants is
further complicated by the involvement of a hypoxia-induced repressor
of HO-1 transcription termed BTB Domain and CNC Homolog 1 (Bach1)
[199]. By contrast to Nrf2, the activity of Bach1 is inactivated by
oxidants and it was shown in human keratinocytes that arsenite-
mediated HO-1 induction involves both the removal of Bach1 from
the HO-1 promoter and the subsequent Nrf2-directed up-regulation in
its expression [200]. Indeed, hypoxia-dependent suppression of HO-1 in
human endothelial cells appears to be regulated by a complex interplay
between Bach1 and Nrf2 [162], which is in turn potentially mediated
by redox-dependent mechanisms.
Although it is well accepted that the Nrf2/HO-1 response is (in part)
oxidant driven, the physiological endogenous source(s) of these oxi-
dants remains unknown. However we have shown that Nox4-generated
H2O2 can activate Nrf2 and induce HO-1 expression in cardiac-speciﬁc
Nox4-overexpressing hearts [155]. Moreover, in vitro simulation of
hemodynamic stress, using phenylephrine-stimulated neonatal rat
ventricular myocytes, resulted in an increase in both Nox4 and Nrf2
protein expression, and a subsequent up-regulation in HO-1 mRNA
expression. This eﬀect was ablated when either Nox4 or Nrf2 were
silenced [156] (Fig. 6). Consistent with these observations, global
Nox4-null mice display reduced HO-1 expression in isolated lung
endothelial cells, an eﬀect that resulted in enhanced apoptosis. This
has been attributed to perturbed CO production as re-introduction of
CO using CORMs enhanced lung endothelial cell survival [46].
Intriguingly, there is also potential for the converse cross talk
between CO- and Nox-dependent signalling mechanisms. Thus it has
been demonstrated that CO administration can act to inhibit the
activity of Nox2 within human airway smooth muscle cells and
neutrophils [201] due to binding to the haem moiety. It will be of
interest to determine whether this is a common regulatory mechanism,
potentially modulating the activity of other NADPH oxidases.
1.12. Hydrogen sulphide
H2S was considered a toxic environmental pollutant until Abe and
Kimura ﬁrst proposed it to be an endogenous cellular signalling
mediator [202]. Subsequent extensive research eﬀorts have established
H2S as a third member of the gasotransmitter family of signalling
molecules and have ascribed to it a number of diverse functions within
diﬀerent physiological systems including the cardiovascular, immuno-
logical and nervous systems [203]. H2S is synthesised endogenously
through the action of 3 pyridoxal 5′ phosphate- (vitamin B6)-dependent
enzymes, cystathionine β-synthase (CBS), CSE and the combined action
of 3-mercaptopyruvate sulphur transferase (3MST) and cysteine amino-
transferase (CAT) [204]. Each of these enzyme systems displays
promiscuity with respect to substrate speciﬁcity and function, and
can additionally catalyse other reactions in the sulphur metabolic
network [205]. These enzymes also display tissue-speciﬁc patterns of
expression. Thus CBS plays a major role in H2S generation in the
nervous system [206], while 3MST is widely distributed in multiple cell
types including neurons, hepatocytes, cardiac cells and endothelial cells
[207,208]. However, within the vascular system, the major enzymatic
source of H2S is CSE, which has been shown to be expressed and be
active in a number of vascular cell types including SMCs [209],
perivascular adipose cells [210] and endothelial cells [211–213]. CSE
is a tetrameric protein and it generates H2S from a number of substrates
including cysteine, cystine and homocysteine [205,214]. Subcellularly
CSE and CBS have been found in the cytoplasm [215], but have also
been suggested to be in the nucleus [216] and under hypoxic conditions
in the mitochondria [217,218]. CAT and 3MST are generally considered
to be localised to the mitochondria (see Fig. 4) [219,220].
The chemical properties of H2S are such that under physiological
conditions in aqueous solutions at pH 7.4, H2S exists in a dissociated
state with approximately two thirds of total H2S existing as hydro-
sulphide anions (HS-) and protons (H+) with the remaining third being
in the form of H2S undissociated, (dissolved) gas. HS- can subsequently
form sulphide ions (S2-) through further dissociation but only at high,
non-physiological pH. [S2-] is therefore considered negligible in phy-
siological systems [221]. Undissociated H2S is a non-polar, lipophilic
molecule which can diﬀuse through membranes in a similar manner to
NO and CO. However, due to its dissociation at physiological pH, H2S
should be considered to be less lipid- permeable than the other
Fig. 6. The inter-relationships between hypoxia, NADPH oxidases and CO. Hypoxia
can act to increase Nox4 expression and H2O2 production, potentially leading to Nrf2
activation and increased HO-1 expression. In opposition to this, hypoxia also increases the
expression of Bach1, a negative regulator of Nrf2 function and HO-1 expression. This
interplay between transcription factors may therefore modulate CO production by HO-1.
CO can itself also inhibit the activity of Nox2.
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gasotransmitter molecules [222], and this may impact on its signalling
functions. The term H2S is typically used collectively to denote both
H2S and HS- anions as it is currently unknown which of these is the
most physiologically relevant species. Once generated, H2S is believed
to function as a secondary messenger by directly modulating the
function of downstream targets. In common with both NO and CO,
H2S can form coordination complexes with metal centres (such as haem
groups) within proteins [223]. In addition, it acts to covalently modify
cysteine residues on target proteins in a process known as S-sulfhydra-
tion [224]. Here, sulphur derived from H2S becomes added to the thiol
group of a target cysteine residue to render the formation of a
hydropersulphide moiety (-SSH). In one study it was shown that as
much as 10–25% of some abundant proteins in mouse liver including
actin, tubulin and glyceraldehyde-3-phosphate (GAPDH) exist in the S-
sulfhydration state under physiological conditions [224]. Further, this
was shown to be mediated by H2S generated enzymatically from L-
cysteine by CSE. Thus the limited number of speciﬁc H2S target proteins
currently identiﬁed [224] seems likely to grow.
1.13. The role of hydrogen sulphide in angiogenesis
One of the ﬁrst biological activities attributed to H2S was in the
regulation of vascular tone [225]. Subsequent research eﬀorts using a
combination of H2S donors [210,226–229] and direct genetic manip-
ulation of the CSE gene have conﬁrmed the physiological relevance of
the CSE/H2S pathway in vasorelaxation and blood pressure regulation
[230]. At the cellular level, studies using patch clamp techniques have
demonstrated that both endogenous and exogenous H2S can directly
hyperpolarize resistance artery VSMCs via modulation of ATP-gated
K+(KATP) channel activity, and that these eﬀects are independent of
cGMP-mediated phosphorylation [231]. More recently, H2S has been
demonstrated to be an endothelial-derived hyperpolarizing factor
(EDHF) which exerts its vasodilatory actions on VSMCs by causing
the opening of KATP channels, at least in part, through S-Sulfhydration
of the Kir 6.1 subunit at cysteine-43 [212]. In addition to its actions as
an EDHF acting on adjacent smooth muscle, H2S signalling is also
thought to be important within endothelial cells themselves. Endothe-
lial CSE can be activated by Ca2+/calmodulin [230] in response to
cholinergic stimulation or by the calcium ionophore, A23187 leading to
enhanced H2S production [230]. Moreover, stimulation of isolated
endothelial cells with ACh resulted in hyperpolarisation in cells isolated
from WT but not CSE-/- mice. This eﬀect is mediated not by KATP
channels but by small and intermediate calcium-gated K+ channels
present within the endothelium, as the hyperpolarisation could be
blocked by apamin and charybdotoxin [212]. Whether speciﬁc cysteine
residues within these calcium-gated K+ channels are targets of S-
Sulfhydration remains to be demonstrated.
H2S has also been shown to be a key regulator of angiogenesis
(Table 1). Thus topical application of H2S to endothelial cells in vitro
increased HUVEC proliferation as well as migration and capillary
morphogenesis on Matrigel, which are considered essential initiating
steps in the angiogenic response [90,232]. In vivo, administration of
NaHS (an H2S donor) increased neovascularisation and haemoglobin
content of Matrigel plugs in mice [232] and, perhaps consistent with
this, also led to improved capillary sprouting and blood ﬂow recovery
in a rat hindlimb ischemia model [233]. The signiﬁcance of CSE-
derived H2S has also been demonstrated in vivo, since both microvessel
formation in response to VEGF and wound healing were impaired in
CSE-/- mice compared to wild-type littermates [90]. In a separate study
H2S was also shown to improve wound healing in type 2 diabetic mice
via the activation of angiopoietin-1 [234]. Clinically, low plasma levels
of H2S and reduced placental CSE expression are associated with
women with pre-eclampsia and it has therefore been suggested that
CSE may have important roles in placenta vascularisation [213].
Mechanistically, several studies have demonstrated that the proan-
giogenic eﬀects of H2S involve the activation of both P13K-Akt and
MAPK signalling pathways [90,211,232]. In this regard it might be
signiﬁcant that Phosphatase and Tensin Homolog (PTEN), a negative
regulator of Akt-signalling has been proposed to be a potential direct
target of H2S-mediated modiﬁcation [235]. There is also increasing
evidence to support the involvement of H2S-mediated modiﬁcation of
KATP channels in the stimulation of the MAPK signalling pathway(s).
Thus it has been shown that the activation of KATP channels per se is
suﬃcient to promote angiogenesis in endothelial cells in vitro [236] and
conversely that KATP inhibitors abrogate VEGF-dependent angiogenic
responses. Moreover, in one study the H2S-dependent activation of p38
MAPK was shown to occur via a KATP channel-dependent mechanism
[90], that was shown to act downstream of VEGF-signalling. In
addition, NaHS administration to tumour-derived human EC cells
resulted in a proangiogenic cellular phenotype that was characterised
by increased K+ and nonselective cationic currents, and increased
cytosolic calcium [237]. These eﬀects were again shown to act down-
stream of VEGF-signalling. CSE was identiﬁed in both these studies as
the relevant endogenous source of H2S, as genetic [90] or pharmaco-
logical [237] ablation of CSE activity in both cases ablated the pro-
angiogenic eﬀects of VEGF. Another potential mechanism of action of
H2S in promoting angiogenesis might be via the modulation of cGMP
levels. As stated above, the importance of sGC/cGMP-dependent
signalling (downstream of VEGF) in angiogenesis has been demon-
strated previously. H2S has been shown to reduce the sGC haem-Fe from
a ferric to a ferrous state, thereby promoting cGMP production [238]. In
addition, H2S is an inhibitor of phosphodiesterase (PDE) activity (which
breaks down cGMP), and therefore can further promote cGMP levels
and signalling functions [239].
Recently the potential roles of miRNAs in the mediation of the
proangiogenic eﬀects of H2S were investigated. miR-640 was identiﬁed
as an miRNA which was signiﬁcantly downregulated in vascular ECs by
H2S treatment and conversely overexpression of miR-640 reduced the
proangiogenic eﬀects of H2S [240]. The altered expression of miR-640
in response to H2S was blocked by inhibition of either VEGFR2 or
mTOR, again suggesting the involvement of VEGF- and Akt-dependent
signalling in the angiogenic response. However, mechanistically, miR-
640 was shown to be a negative regulator of HIF1α, via direct binding
to 3′UTR sequences within HIF1α mRNA. Perhaps consistent with these
observations, the loss of CSE-derived H2S has been shown to be
associated with decreased HIF-1α [241]. Thus H2S may potentially
act upstream as well as downstream of VEGF-signalling to promote
angiogenic responses and a feed-forward cycle between H2S production
and HIF-signalling has been proposed [242]. CSE-derived H2S produc-
tion has also been implicated in the negative regulation of expression of
anti-angiogenic factors. For instance, CSE silencing in HUVEC resulted
in the increased release of soluble fms-like tyrosine kinase I as well as
soluble endoglin [213], while over-expression of CSE conversely
dampened their release. Moreover, administration of the slow-releasing
H2S donor, GYY4137, caused a reduction in circulating levels of these
anti-angiogenic factors. Therefore H2S may potentially act upon multi-
ple (potentially inter-related) signalling pathways to modulate the
cellular angiogenic response.
1.14. Regulation of hydrogen sulphide-signalling by redox-dependent
mechanisms
As is the case for NO and CO, the signalling functions of H2S that
involve binding to metal centres can be modulated by the redox state of
the coordinated metal ion, which in turn may be modulated by both the
“steady state” redox potential of the cellular environment and/or the
localised production of reactive oxygen species such as O2- or H2O2. In
addition, the signalling mechanisms of H2S which involve thiol
modiﬁcation may also be subject to redox-dependent regulation. The
precise mechanism through which H2S induces its modiﬁcations
remains contentious. It was thought initially that H2S attacks previously
oxidised cysteine residues such as those in the sulphenic acid (SOH) or
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disulphide bonded (S-S) state in a reduction reaction [224]. However
recent studies have suggested that in order to mediate its function, H2S
acts as an oxidant molecule through an initial reaction with H2O2 to
form polysulphides (H2Sn). These polysulphides can then oxidise
cysteine residues on target proteins yielding the persulphide moiety
[226,235]. Such a mechanism of H2S-mediated oxidative activation,
ultimately resulting in the formation of an intermolecular disulphide
bond, has been demonstrated in the case of PKG [226]. Moreover, the
H2O2-dependent conversion of H2S to polysulphides results in the loss
of polarity, and therefore greater lipid solubility of the signalling
moiety. This therefore potentially increases the ability of H2S to signal
to adjacent cells, and may be an important contributory factor in
regulating the signalling functions of H2S.
Another potential level at which reactive oxygen species may act to
mediate H2S-dependent signalling is by regulation of CSE-dependent
H2S production. At the level of gene expression, Wang et al. showed
that exogenous H2O2 increased the activity of the CSE promoter [243]
while in another study CSE transcription was upregulated in rat
mesangial cells by treatment with platelet-derived growth factor, and
this upregulation was abolished by antioxidants including NAC and the
Nox inhibitor, DPI [244]. However in the interpretation of these results
it should be noted that DPI is an inhibitor of all ﬂavoproteins, including
NOS [245]. A potential role for Nox4 in the transcriptional regulation of
CSE is also suggested by studies conducted in our group. Thus we have
demonstrated that in endothelial cells in vitro, Nox4-generated H2O2
acts as a positive regulator of CSE transcription, via activation of a
haem-regulated inhibitor kinase/ eIF2α/activating transcription factor
4 (ATF4) signalling module and CSE was found to be a direct
transcriptional target of ATF4 [246]. In vivo, endothelial-speciﬁc
Nox4 transgenic mice exhibited lowered blood pressure [48] and a
hypo-contractile phenotype in response to phenylephrine that was
abolished when vessels were incubated with the CSE inhibitor, propar-
gylglycine [246]. We therefore conclude that Nox4 may be a physio-
logically relevant source of H2O2 that positively regulates CSE expres-
sion and H2S production [246] in endothelial cells (Fig. 7).
In addition to playing a role in the transcriptional regulation of CSE,
H2O2-dependent signalling may also modulate CSE activity. Thus in
HUVECs it was shown, using a cell-trappable ﬂuorescent H2S probe,
that VEGF application acted to increase CSE-derived H2S production in
a H2O2- dependent manner. The relevant source of H2O2 in these
experiments was again suggested to be a Nox, as the increase in H2S
production could be inhibited by DPI (although, as stated above, DPI is
not a speciﬁc Nox inhibitor). Clearly, however, crosstalk between H2S
and H2O2, in endothelial cells after VEGF-activation, may be important
in the regulation of angiogenic cellular responses [247].
1.15. Interactions between gasotransmitters
The sequential discovery and characterisation of each of the
gasotransmitters had initially led them to be considered as biologically
distinct entities that mediate their functions independently of each
other. While this is no doubt the case in certain settings, it has become
apparent that considerable synergistic and antagonistic interplay occurs
between this family of gases at multiple levels creating a multifaceted
signalling platform though which key cellular and physiological
processes, such as angiogenesis, are orchestrated [87]. Coletta et al.
studied the synergistic eﬀects of H2S and NO in the angiogenic
response. Here, the pro-angiogenic eﬀects of H2S were ablated in
endothelial cells isolated from eNOS gene-deﬁcient mice. Conversely
the silencing of CSE and concomitant reduction in H2S production
prevented NO-stimulated angiogenesis. Mechanistically, the mutual
dependency between H2S and NO in the endothelium occurs on
multiple levels and appears to be centred on the production of cGMP.
NO is known to bind to and activate sGC leading to elevated cGMP
production. By contrast H2S inhibits phosphodiesterase-5 (PDE5) pre-
venting cGMP degradation. Furthermore H2S was also shown to
enhance NO production in endothelial cells. Thus these gasotransmit-
ters act in synergy to potentiate the eﬀect of cGMP leading to protein
kinase G (PKG) activation and subsequent modulation of key aspects of
angiogenesis [123]. Interestingly, the haem group of sGC can be bound
and activated by CO and NO but with varying aﬃnities. CO, for
example, binds at lower aﬃnity than NO, an observation that may
relate to compensatory actions of the gases [248]. By contrast H2S can
reduce the haem iron of sGC from its ferric form to its ferrous form, an
eﬀect that promotes the binding of NO [238]. This ability for a single
protein to become the target of multiple gasotransmitters has been
shown to extend to a number of other proteins such as GAPDH which
can be S-sulfhydrated by H2S and nitrosolated by NO [224].
The interrelationship between NO and CO extends further as it has
been shown that NO can stimulate HO in the endothelium [249] but
inhibit it in the brain [250]. To add a further layer of complexity to the
interplay between the gases, it is becoming apparent that they may be
able to react together to form novel signalling intermediates. Indeed the
NO donor sodium nitroprusside (SNP) and H2S can react to form
nitroxyl (HNO) [251] which has been shown to elicit anti-angiogenic
eﬀects in tumours [252]. Taken together it is clear that the eﬀects of
these gases cannot be viewed simply in terms of their individual
functions and must be considered as part of a more complex system,
in which many aspects of their biology are crucial, including, for
example, their subcellular location. It is conceivable that compartmen-
talisation of the gasotransmitter producing enzymes into the same
subcellular location may facilitate the interaction of their respective
gases thereby helping to ﬁne-tune the varied signalling responses
associated with them. Perhaps consistent with this notion, O2- and
H2O2 (enzymatically produced in a highly-regulated, compartmenta-
lised manner), can potentially act in a similar way through varied and
complex interactions with the gasotransmitters to yield diverse signal-
ling molecules such as polysulphide [226] and peroxynitrite [253]. A
greater understanding of the chemistries and interrelated actions of
these gases is now very much needed and will no doubt lead to a fuller
understanding of their roles in many biological processes, including
angiogenesis.
2. Conclusion and future perspectives
In the last decade the conventional paradigm of reactive oxygen
species as deleterious by-products of aerobic metabolism has shifted,
and now it is largely accepted that they represent a group of highly
regulated and coordinated secondary messengers capable of mediating
a number of physiological processes [254] including angiogenesis. In
Fig. 7. Redox-dependent mechanisms regulating H2S production by CSE. A) H2O2
(generated from an unknown source) can enhance CSE activity. B) Nox4 represents a
potential source of H2O2 that can upregulate the transcriptional expression of CSE
through an ATF4-dependent mechanism. C) NADPH-derived O2-/H2O2 can activate Nrf2
leading to increased CSE transcription. These redox-dependent transcriptional and post-
translational changes in CSE expression may lead to altered H2S production. CSE:
Cystathionine-γ-lyase.
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particular, H2O2 has been shown to induce endothelial cell phenotypes
such as increased proliferation, tube formation and migration that are
all fundamental to the angiogenic response [52]. Nox enzyme com-
plexes have emerged as the signiﬁcant endogenous sources of O2- and
H2O2 within the vasculature and Nox4, in particular, seems a likely
generator of the H2O2 shown to be important in the angiogenic cellular
response. Thus Nox4 is highly expressed in vascular cells compared to
other Nox isoforms, and its expression increases in response to tissue
hypoxia [67], a condition in which many pro-angiogenic factors such as
VEGF are released. Secondly, by contrast to Nox1 and Nox2 which
generate O2-, Nox4 is considered to be a generator of H2O2, the oxidant
species shown to be most pro-angiogenic [53]. Lastly, genetic gain- and
loss-of-function models, both in vitro and in vivo, have consistently
highlighted a positive role for Nox4 in ischemia-induced angiogenesis
[46,49].
The roles of reactive oxygen species, notably Nox-generated O2- and
H2O2, in orchestrating the angiogenic cellular responses are being
demonstrated to be increasingly complex and diverse. Moreover it is
clear that their functions are intimately connected to those of the
gastransmitters, NO, CO and H2S. The production of all these reactive
signalling molecules occurs in a highly coordinated manner, close to
their biological sites of action. They can also act independently,
synergistically or antagonistically to elicit their downstream eﬀects
often culminating in a highly ﬁne-tuned response. The transient
chemical nature of the gasotransmitters, as well as their inherent need
to be produced at their sites of action, and their toxicity in non-
physiological concentrations, precludes their direct use in modulating
angiogenesis therapeutically. However, the potential use of (sometimes
slow-releasing) donor compounds of NO, CO and H2S as clinical
therapeutics is being vigourously explored [255]. In this regard a
critical issue is the adverse, oﬀ target, potential pro-oncogenic eﬀects
which might be induced by promoting angiogenesis. Thus it will be
necessary to speciﬁcally target the activity of such drugs, and a better
understanding of the complexity of the interplay within and between
diﬀerent reactive oxygen species and the gasotransmitters is crucial.
This represents a major challenge to the scientiﬁc community, and
better methodologies to measure the physiological (and pathophysio-
logical) levels of these mediators accurately and eﬃciently both in vitro
and in vivo are in high demand. Interestingly, donor molecules have
begun to be designed which exploit the beneﬁcial synergistic actions of
the gasotransmitters. One such molecule; ZYZ-803, is a novel H2S- NO
hybrid molecule which has been shown to exhibit greater proangio-
genic potency than either H2S or NO alone [256]. It can be hoped that
in the future a more integrative approach to studying the roles of the
gasotransmitters in angiogenesis, and their modes of regulation by
diverse redox-dependent mechanisms may lead to the development of
more eﬃcacious therapeutic strategies.
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